Skip to main content
  • Record revenue from product sales, up 96% on 2017
  • Pharming’s first half year of net profitability
  • Expanding pipeline of new products plus new large indications and dosage forms for RUCONEST®

“We are delighted with the further progress we have made expanding the reach of RUCONEST®, allowing more patients to access the clinical benefits of our product.”

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline